Iterum Therapeutics plc (ITRMF) Cash from Financing Activities (2018 - 2025)

Iterum Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $5.4 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities changed 0.04% year-over-year to $5.4 million; the TTM figure through Sep 2025 stood at $16.0 million (up 19.68% YoY), while the FY2024 annual figure was $26.7 million, up 2481.33% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $5.4 million, up from $5.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $87.0 million in Q1 2021, with the low at -$8.4 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is $235000.0 (2023), against an average of $6.5 million.
• The sharpest annual moves came in 2021 and 2024: Cash from Financing Activities plunged 313.04% in 2021, then jumped 54200.0% in 2024.
• Iterum Therapeutics' Cash from Financing Activities stood at -$1.6 million in 2021, then jumped by 126.58% to $433000.0 in 2022, then surged by 36.03% to $589000.0 in 2023, then soared by 2256.03% to $13.9 million in 2024, then slumped by 60.86% to $5.4 million in 2025.
• Business Quant data shows ITRMF's Cash from Financing Activities at $5.4 million in Q3 2025, $5.1 million in Q2 2025, and -$8.4 million in Q1 2025.